[Pharmacoeconomics of the New Antidepressants and Antipsychotics]
This review summarizes results of cost-utility analyses done with newer versus older antidepressants as well as atypical versus conventional/typical neuroleptics/antipsychotics. Following descriptions of the methodological principles, the currently available studies (simulation models) are presented and discussed critically. It can be stated that the economic value of different antidepressants and the atypical neuroleptics can not be decided definitively at the present time due to methodological reasons (e. g. lacking of randomized prospective studies). Increased quality of life of patients and their family seems true for the newer psychotropics, measurement is difficult, however, and a challenge for social and ethical discussions.